Concord Biotech profitability ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
Returns
13.6%13.6%22.3%21.9%
12.1%12.1%19.9%18.1%
15.0%15.0%26.5%24.3%
15.1%13.7%22.7%22.1%
Margins
34.5%34.8%42.2%42.4%
27.8%27.8%37.7%37.2%
—109.5%40.4%—
32.0%32.4%41.3%40.2%
23.9%24.6%31.0%30.3%
24.1%24.7%31.0%30.3%
16.3%16.3%11.1%17.7%
Additional
25.3%25.0%24.8%25.5%
—43.2%24.6%23.2%
13.6%7.7%16.8%16.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CONCORDBIO₹1,225.00

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹12,815 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Returns
Return on Common Equity—21.8822.2613.6313.63
Return on Assets—18.1219.9012.1412.14
Return on Capital Employed—24.2526.5214.9614.96
Return on Invested Capital—22.0922.7313.7215.14
Margins
EBITDA Margin—42.4442.1934.8334.54
Operating Margin—37.1737.6627.7727.77
Incremental Operating Margin——40.40109.52—
Pretax Margin—40.2441.3232.4031.98
Net Income Margin—30.3030.9724.5723.87
Net Income to Common Margin—30.3030.9724.7324.13
FCF Margin—17.6811.1116.2816.28
Additional
Effective Tax Rate—25.5324.7925.0025.29
Dvd Payout Ratio—23.1924.6343.18—
Sustainable Growth Rate—16.8116.787.7413.63
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.